

Office Address:
C. Porumbescu, Str. Nr. 59,
Timisoara, 300239, Romania

Phone: +40-256-495403
+40-745-148485 (mobil)
Fax: +40-256-201041
E-mail: coprean@yahoo.com

Cristina Marinela Oprean, MD

Personal dates

Professional registration number: 869035

Education/

Board Certification s

- 2024.- ESO& Ulm. University Certificate of Competence in Breast Cancer
- 2011- **Specialist Clinical Pharmacology.Medicine University Timisoara**
- 2008-**Senior Specialist in Medical Oncology License - Cluj. Romania**
- 2006-MBA.Certificate- **British Academy of Business,Communication**
- 2003-Specialist in Medical Oncology License - Bucharest. Romania
- 2001-General abdominal ultrasound competence - Timisoara. Romania
- 1999-Specialist General Practitioner License - Timisoara. Romania
- 1989-1995.M.D- **Medical Doctor License-University of Medicine Timisoara**
- 1985-1989.High School Diploma- High School for Nurse Timisoara

Postgraduate e courses /trainings

- 2022-2024 - European School of Oncology Postgraduate Program-
Certificate of Competence in Breast Cancer Course
- 2011.8-9.April. European School of Oncology Course. Viareggio. Italy
"Gene Profiling in Clinical Oncology"
- 2011.April.1. European School of Oncology Course . Stresa. Italy
"Rare Solid Cancers-an Introduction"
- 2010.December. 5-7.Dermatology Department . University of Kiel
Germany -19th Melanoma Perceptorship Meeting
"Sentinel Node Biopsy and adjuvant Treatment"
- 2010-May.01-31 EUSOMA-ESO-ESSO-Training Project. Oncology
Department Frauenkliniken der Ludwig-Maximilians University Munich.
"The Multidisciplinary Approach on Breast Cancer Care"
- 2009.June.11-12 European School of Oncology Course. Dublin. Ireland
"Evidence Based Oncology"
- 2009.May.6-7.IMPACT Breast Cancer Conference. Brussels. Belgium
" Pre-IMPACT Training Course "- Susan.G.Komen for the cure Grant
- 2009.March21-26 European School of Oncology Course.Sintra.Portugal
"8th Masterclass in Clinical Oncology " -participation with ESO Grant
- 2008.October.30-3rd Annual Multidisciplinary Symposium. Paris. France
" Improving Clinical Outcomes in Genitourinary Malignancy"
- 2008.April.03-04. 3rd Central European Course. Vienna. Austria
"Methodology of Clinical Trials in Oncology"
- 2007.November.17.PRIME Oncology Course. Athens.Grece
"Expert Practice in Breast Cancer"
- 2007.November.24.PRIME Oncology Course .Nice.France.
"Expert Practice in Lung Cancer"
- 2006.November.18.ONE Course. Berlin, Germany
"Challenging Cases in Breast Cancer"
- 2006.October.6-7.ONE Course.MonteCarlo.Monaco
"Improving Clinical Outcomes in Genitourinary Malignancy"
- 2006.September.7-9.ESO Course. Stockholm. Sweden
"Palliative Cancer Care"
- 2006.May.12-13.ESO Advanced Course. Belgrade. Serbia

"Evidence Based Management of Lung Cancer"
 -2005.June.25.CESAR Course.Vienna.Austria
"State of art in treatment of breast cancer"
 -2005.May.28-30.ESO Advanced Course. Milocer. Republic Muntenegro
"Advances in Clinical Oncology"
 -2005.April.13-15.ESMO.Translational Research Visit. Barcelona. Spain
"Early Clinical Development of Molecular Target Therapies"
 -2004.June.17-19: ESMO Advance Course .Rhodes. Greece
"New Perspectives: Chest Tumors Integration of Research "
 -2004.Marh.6-11European School of Oncology Course.Limassol.Cyprus
"Masterclass in Clinical Oncology", participation with an ESO Grant
 -2003.September.4-6: ESMO Course Warsaw. Poland
"Principles and practices in Medical Oncology"
 -2003.August. 18-21: Vienna School of Clinical Research.Vienna.Austria
"Publication workshop" -participation with a VSCR Grant
 -2003.June.21-27: 5th FECS/AACR/ASCO Workshop .Flims.Switzerland.
"Methods in Clinical Research"
 -2003.May. 26-28. Vienna School of Clinical Research . -Vienna. Austria
"Advanced Good Clinical Practice for experts in clinical research"

**Professional
 qualification
 s and
 experience**

Current positions:

- **Reviewer** for papers in oncology field in international medical journals-
 since 2021 January
 - **Chef of Oncology Day Hospital. Oncohelp.Timisoara.Romania**-since
 May 2015 -present
 -**Specialist in Clinical Pharmacology Consultant Oncohelp Hospital**
 Timisoara- since 2011
 -**Scientific advisor - oncology field for Pharma Industry** –since 2010
 -**Senior Specialist in Medical Oncology**- since October 2009- Oncohelp
 Hospital – Timisoara. Romania
 - **Senior Specialist in Medical Oncology**- since December 2008.
 Oncomed Outpatient Unit - Timisoara. Romania.
 - **Principal Investigator in Clinical Trials in Oncology**- since December
 2008 in 70 clinical studies phase II, III and IV in colon, pancreatic, lung,
 gastric, malign melanoma, breast, prostate, ovarian, head and neck
 cancer and supportive cancer care
 - **Subinvestigator in clinical trials in oncology** since 2001- in 100
 clinical studies in lung, breast, ovarian, colon, gastric, prostate ,malign
 melanoma, pancreatic cancer and supportive care

Past positions:

-**Chef of Oncology Compartment**; Senior Specialist Consultant in
 Medical Oncology Military Hospital Timisoara April 2012- April 2015
 - **Chef of Oncology Department** Oncohelp Hospital. Timisoara.
 Romania 1st July 2011- 1st April 2012
 - **Specialist in Medical Oncology**- 2004-2008. Oncomed. Timisoara
 - **Resident in Medical Oncology**-1999- 2004. City Hospital. Oncology
 Department. Timisoara. Romania.
 -**Study coordinator in clinical trials** - 2004 - 2008 in 30 clinical studies
 phase II,III,IV in the same indication in oncology
 -**Resident in General Medicine (Family Doctor)**-1999-1996. County
 Hospital. Family Medicine Department . Timisoara. Romania
 -**Nurse** in Internal Medicine -1993 -1995 part time . County Hospital.
 Internal Medicine Department. Timisoara. Romania

**Publications
list**

- 1."Real World, National Study of Palbocicib in HR+/HER2-Metastatic Breast Cancer: A 2,5 Years Follow-Up"
PALBO01/2021" *Diagnostics*.05.May.2025. DOI 10.3390/15091173.
- 2."Risk factors for cancer recurrence in postmenopausal women: a bibliometric study". *Frontiers in Oncology* .Vol 15.
01.April.2025.DOI.10.3389/fonc.2025.1522713
- 3."Perception of disease, dyadic coping, and the quality of life of oncology patients in the active treatment phase and their life partners: an approach based on the actor-partner interdependence model", *Front. Psychol.*14.Apr.2024.DOI:10.3389/fpsyg.2023.1069767
- 4."Interim Analysis Results from a European Registry Study Aimed to Prospectively observed Patterns and Outcomes in Patients with Her2+ Unresectable Locally Advanced or Metastatic Breast Cancer" *Cancer Research*.2023.March.01.DOI 10.1158/1538-7445.SABCS22-P3-02-05
- 5."Pregnancy in a Young Patient with Metastatic HER2-Positive Breast Cancer-Between Fear of Recurrence and Desire to Procreate", *Current Oncology*.08.May.2023.30,4833-4843.
DOI:10.3390/curroncol30050364
- 6."Attitudes towards COVID-19 vaccination in patients with cancer: A cross-sectional study of 12 oncology centers", *Molecular and Clinical Oncology*2022.17.122.September.23.2022.DOI/10.3892/mco.2022.2595
- 7."Spectrum of BRCA1/2 Mutations in Romanian Breast and Ovarian Cancer Patients" *Int. J. Environ. Res. Public Health* 2022, 19,4314.
April.04.2022./DOI:10.3390/ijerph19074314
- 8."Management of HER2-Positive Breast Cancer for a Young Patient with Visceral Crisis-The Adjuvant Role of Lifestyle Changes" *Curr. Oncol.* 2022, 29, 1890-1901.March.10.2022. DOI: 10.3390/curroncol29030154
- 9."The Pattern of Second Primary Tumors in Postmenopausal Women with Prior Breast Cancer in Western Romania: A Retrospective, Single-Institution Study", *Diagnostics*,2021,11,1957.
October.22. 2021, DOI:10.3390/diagnostics11111957
10. "Well-Being, Depression, and Anxiety following Oncoplastic Breast Conserving Surgery versus Modified Radical Mastectomy Followed by Late Breast Reconstruction". *International Journal of Environmental Research and Public Health* 18(17):9320.
September.2021. DOI: 10.3390/ijerph18179320
- 11."Carcinomatous-like mastitis due to axillary lymphadenopathy in a case of nasopharyngeal carcinoma: A case report". *Experimental and Therapeutic. Medicine*. July.2021. DOI: 10.3892/etm.2021.10458

12. "Updated Overall Survival Analysis From IMpower110: Atezolizumab versus Platinum-Based Chemotherapy in Treatment-Naive PD-L1-Selected Non-Small Cell Lung Cancer". *Journal of Thoracic Oncology*. July. 12. 2021. DOI: [10.1016/j.jtho.2021.06.019](https://doi.org/10.1016/j.jtho.2021.06.019)
13. "Comparative hematological profiles for dose-dense vs. regular anthracycline-based neoadjuvant chemotherapy in non-metastatic breast cancer" *Experimental, and Therapeutic. Medicine*. 11. May. 2021. DOI: [10.3892/etm.2021.10179](https://doi.org/10.3892/etm.2021.10179)
14. "Unilateral Orbital Metastasis as the Unique Symptom in the Onset of Breast Cancer in a Postmenopausal Woman: Case Report and Review of the Literature" *Diagnostics* 2021, 11, 725. April. 19. 2021. [Doi.org/10.3390.diagnostics11040725/](https://doi.org/10.3390/diagnostics11040725/)
15. "Skin-Reducing Mastectomy and Immediate Reconstruction for a Large Recurrent Borderline Phyllodes Tumor", *Applied Science*. 29. January 2021, 11, 1224. [Doi./10.3390/app11031224](https://doi.org/10.3390/app11031224)
16. "Endurance of erythrocyte series in chemotherapy" *Experimental&Therapeutic. Medicine*. 2020 December. 20(6):214. DOI: [10.3892/etm.2020.9344](https://doi.org/10.3892/etm.2020.9344)
17. "Postmenopausal Breast Cancer in Women, Clinical and Epidemiological Factors Related to the Molecular Subtype: A Retrospective Cohort Study in a Single Institution for 13 Years. Follow-Up Data", *International Journal of Environmental Research and PublicHealth*. November 24. 2020. 17(23). 8722. DOI [10.3390/ijerph17238722](https://doi.org/10.3390/ijerph17238722)
18. "Determining factors of renal dysfunction during cisplatin chemotherapy". *Experimental, and Therapeutic. Medicine* November. 26. 2020. DOI: [10.3892/ETM.2020.9516](https://doi.org/10.3892/ETM.2020.9516)
19. "Veliparib with carboplatin and paclitaxel in BRCA mutated advanced breast cancer(BROCADE3): a randomized, double-blind, placebo-controlled, phase 3 trial", *The Lancet Oncology*. 2020 Oct; 21(10):1269-1282. [Doi: 10.1016/S1470-2045\(20\)30447-2](https://doi.org/10.1016/S1470-2045(20)30447-2). Epub 2020. Aug 27
20. "Patient-reported outcomes (PROs) in the randomized, phase III IMpower110 study of atezolizumab vs chemotherapy in 1L metastatic NSCLC". *Journal of Clinical Oncology*. 38(15 suppl):9594-9594. May 2020. DOI: [10.1200/JCO.2020.38.15_suppl.9594](https://doi.org/10.1200/JCO.2020.38.15_suppl.9594)
21. "The influence of cognitive schemas on mixed anxiety-depressive symptoms of breast of breast cancer patients". *BMC Womens Health*. 2020. Feb. 24; 20(1):32. doi. [10.1186/s12905-020-00898-7](https://doi.org/10.1186/s12905-020-00898-7)
22. "LBA9Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer". *Annals of Oncology* 30 (Supplement 5). October. 2019. DOI: [10.1093/annonc/mdz394.008](https://doi.org/10.1093/annonc/mdz394.008)
23. "Efficacy and safety of CetuGEX in reoccurrence/metastatic squamous cell carcinoma of head and neck (RM-HNSCC): Results from the randomized phase II RESGEX study". *Journal of Clinical Oncology* 36, nr 5 suppl. February 10, 2018, 59-59
24. "Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients". *European journal of cancer (Oxford, England; 1990)* 82. June. 2017. DOI: [10.1016/j.ejca.2017.05.010](https://doi.org/10.1016/j.ejca.2017.05.010)
25. "Effectiveness and safety profile of ipilimumab therapy in previously treated patients with unresectable or metastatic melanoma-the Romanian Patient Access Program". *J BUON*. Vol 23. Issue 5. 2017 Sep-Oct; 1287-1295

first IMPAKT Breast Cancer Conference held in Brussels. Belgium
 -2008.June- **MASCC.Travel Scholarship** for participation at MASCC/ISO
 International Symposium Supportive Care in Cancer. Houston. Texas
 -2007.March- "**CELER Award 2006** – the top recruiter of this year"- Central
 European Society for Anticancer Drug Research. St.Gallen. Schweiz
 -2005.April- **ESMO TRU Visit Grant**. Vall d'Hebron Hospital. Barcelona
 -2004- **I Prize** Liberate's quiz competition Investig. Meeting.Antalya. Turkey
 -2003-**II.Prize** quiz competition Cell-Therapeutics Investig. Meeting.Lisbon.
 -1997.January - **SOROS scholarship** for Timis county for participation at
 "Emergency Medicine Course", held in Targu Mures. Romania

**Professional
membership**

-Romanian Society of Medical Oncology - since December 1999
 -European Society of Clinical Oncology(ESMO) – since September 2002
 - Multinational Association of Supportive Care in Cancer(MASCC)since 2007
 - European Association for Cancer Research(EACR)-since 2008

Languages

-ENGLISH	-Read/	Write/	Speak:	Fluent/	Fluent/	Fluent
-FRENCH	-Read/	Write/	Speak:	Good/	Good/	Some
-GERMAN	- Read/	Write/	Speak:	Good/	Good/	Good

Dr Cristina Oprean . 05.June.2025

On

26. "NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron", Supportive Cancer Care, Nov. 26. 2016
27. "Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)", Frontiers in Oncology. Article 232. Volume 6. October. 31. 2016
28. "The benefit of Fasodex administration in metastatic breast cancer"-case presentation "Oncologia AZi"-nr5/November 2014pg4
29. "Randomized phase II study of MEHD 7945A(MEHD)vs Cetuximab(CET) in >1 line recurrent/metastatic squamous cell carcinoma of the head & neck progressive on/after platinum based chemotherapy" Abstract 9860 -Annals of Oncology Volume 25, Supplement 4, September 2014
30. "A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy"; Annals of Oncology vol 25, Nr7. July 2014 ISSN 1328-1333
31. "No evidence of increased cyclophosphamide toxicity associated with the antiemetic agent NEPA, a fixed dose combination of Netupitant and Palonosetron " poster presentation abstract 2949- 55th ASH Annual Meeting New Orleans. December 2013
32. "DORINTA-the support group for breast cancer patients" –poster presentation 2012 International MASCC Symposium NY June 2012 abstract 156 ; Supportive cancer care 2012 Nr 20 Suppl1 pg S44
33. "Principles of Medical Oncology "- chapter in book "General Oncology". 2011. Victor Babes Editure Timisoara. Romania
34. "CELER: an international randomized phase III trial of the CESAR Group: should chemotherapy be added to hormonal therapy in advanced breast cancer?"; The Breast vol 16(Supp 1). March 2007
35. "The Impact of Psychological Interventions on Breast Cancer Patients. A Romanian Pilot Study"; Psycho-Oncology 15 (Supp.2), Oct. 2006, S422-423, ISSN 1057-9249
36. "Results of a patient information campaign using a printed material"- abstract- Annals of Oncology volume 17, 2006, Supplement 9, pg ix281
37. "Oncomed- an oncology unit in Romania"-poster presentation. Improving Cancer Services Conference. March. 2005. Milano. Italy
38. "Lung cancer in elderly"-chapter in book "Lung diseases in elderly". 2004.
39. "Clinical Oncology"-chapter in book "Psycho-Oncology" 2003. Mirton. Editure. Timisoara. Romania
40. "The results of psychotherapeutic interventions on patients with cancer disease"- oral presentation. National Romanian Psychiatry Conference. October. 2002. Timisoara. Romania
41. "Management of febrile Neutrogena after chemotherapy"- database. National Oncology Conference. November .2001. Bucharest. Romania
42. "Achantosis Nigricans – para-neoplastic syndrome at a patient with nonsmall lung cancer" -case presentation. Romanian 's Society of Radiotherapy Conference. October. 2001. Oradea. Romania

**Awards
received**

-2010-May. 01-31 **EUSOMA-ESO-ESSO-Grant for Training Project** –visiting doctor in a Breast Cancer Unit-Frauenkliniken der Ludwig-Maximilians University. Munich

-2009. May. **Susan. G Kommen for the Cure Travel Grant** for participation at